Molecular Subtype
Chronic Myeloid Leukemia, BCR-ABL1 Positive
CI-CAN-00002365CMLExplore in graph →
Hematologic102 active trials3 approved drugs320 evidence items
- NCIt
- C3174
- OncoTree
- CMLBCRABL1
- DOID
- 0081088
- DOID
- 8552
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00002365CMLExplore in graph →
Clinical trials
649 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (104)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05433532 | Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients | completed | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT04793399 | Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients | terminated | Phase 1 / Phase 2 | 9 | Fundacion Espanola para la Curacion de la Leucemia Mieloide CronicaOTHER |
| 1 |
| Mar 19, 2024 |
| clinicaltrials |
| NCT01858740 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children | completed | Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT01904136 | Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03128359 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | completed | Phase 2 | 38 | City of Hope Medical CenterOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05201183 | A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Naoyuki G. Saito, M.D., Ph.D.OTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT00540995 | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer | terminated | Phase 1 / Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT03193281 | KISS Study: Kinase Inhibition With Sprycel Start up(KISS) | unknown | Phase 2 | 91 | University of Auckland, New ZealandOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03455517 | Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia(VeRitAs) | completed | Phase 2 | 77 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT01823198 | Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | completed | Phase 1 / Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT03096782 | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | completed | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT01428635 | Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy | completed | Phase 2 / Phase 3 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | terminated | Phase 2 | 20 | University of NebraskaOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT03267186 | Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant | completed | Phase 2 | 8 | Andrew RezvaniOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02311998 | Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | completed | Phase 1 / Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT01572662 | Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning | completed | Phase 2 | 201 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01593254 | Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib(DASCERN) | completed | Phase 2 | 262 | Bristol-Myers SquibbINDUSTRY | 15 | Jun 22, 2023 | clinicaltrials |
| NCT03883087 | A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation | unknown | Phase 2 | 41 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT00354120 | Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant(GLOBAL) | completed | Phase 2 / Phase 3 | 121 | Gruppo Italiano Trapianto di Midollo OsseoOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT00796068 | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant | completed | Phase 2 | 130 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT02543749 | DC Vaccination in CML | terminated | Phase 1 / Phase 2 | 1 | Charite University, Berlin, GermanyOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT02810990 | Bosutinib in Elderly Chronic Myeloid Leukemia(BEST) | completed | Phase 2 | 65 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Feb 3, 2023 | clinicaltrials |
| NCT00573378 | Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia | terminated | Phase 2 | 12 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT05638763 | Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia | unknown | Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT01850004 | Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response(DASFREE) | completed | Phase 2 | 84 | Bristol-Myers SquibbINDUSTRY | 6 | Nov 3, 2022 | clinicaltrials |
| NCT02556931 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | completed | Phase 2 | 117 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT03852407 | Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning(HLA) | recruiting | Phase 2 | 114 | University of LiegeOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04006847 | Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 1 | Milton S. Hershey Medical CenterOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT01667133 | A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) | completed | Phase 1 / Phase 2 | 35 | Ariad PharmaceuticalsINDUSTRY | 1 | Jun 13, 2022 | clinicaltrials |
| NCT00968864 | T-cell Depleted Alternative Donor Transplantation | terminated | Phase 2 | 53 | Wake Forest University Health SciencesOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT02353728 | Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy | completed | Phase 2 | 16 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 25, 2022 | clinicaltrials |
| NCT04835584 | KRT-232 and TKI Study in Chronic Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 109 | Kartos Therapeutics, Inc.INDUSTRY | 8 | Mar 21, 2022 | clinicaltrials |
| NCT00481052 | Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase(CML0307) | completed | Phase 2 | 74 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 18, 2022 | clinicaltrials |
| NCT00462943 | Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML | completed | Phase 2 | 100 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 10 | Dec 28, 2021 | clinicaltrials |
| NCT02795520 | Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia | terminated | Phase 1 / Phase 2 | 32 | OncoTherapy Science, Inc.INDUSTRY | 1 | Nov 24, 2021 | clinicaltrials |
| NCT00375219 | Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation | completed | Phase 2 | 103 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 10 | Nov 15, 2021 | clinicaltrials |
| NCT02078960 | A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study) | terminated | Phase 1 / Phase 2 | 10 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 4 | Nov 9, 2021 | clinicaltrials |
| NCT00210119 | Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response(AFR22) | terminated | Phase 2 | 19 | Institut BergoniéOTHER | 1 | Nov 8, 2021 | clinicaltrials |
| NCT00488592 | Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers | completed | Phase 2 | 10 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 12, 2021 | clinicaltrials |
| NCT03602898 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 30, 2021 | clinicaltrials |
| NCT00171158 | An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis | completed | Phase 2 | 260 | Novartis PharmaceuticalsINDUSTRY | 4 | Jun 25, 2021 | clinicaltrials |
| NCT00860574 | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia | completed | Phase 2 | 96 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT04883125 | Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment | completed | Phase 2 | 90 | Mansoura UniversityOTHER | 1 | May 12, 2021 | clinicaltrials |
| NCT02707393 | Allogeneic Stem Cell Transplantation for Children With CML | completed | Phase 2 / Phase 3 | 13 | St. Anna KinderkrebsforschungOTHER | 3 | Apr 15, 2021 | clinicaltrials |
| NCT01216085 | An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints(CML) | completed | Phase 2 | 10 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 10, 2021 | clinicaltrials |
| NCT02973711 | A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT00489203 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 140 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04709731 | Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia(CarPAs) | unknown | Phase 2 | 50 | Associazione Italiana Pazienti Leucemia Mieloide CronicaOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT01207440 | Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)(PACE) | completed | Phase 2 | 449 | Ariad PharmaceuticalsINDUSTRY | 11 | Feb 2, 2021 | clinicaltrials |
| NCT01445080 | Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | completed | Phase 1 / Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Feb 2, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Apr 25, 2024source: clinicaltrials